Abstract
Major depressive disorder (MDD) and bipolar disorder (BD) are conditions of high prevalence and significant global impact, with associated costs exceeding $500 billion annually. Treatment-resistant forms of these disorders are associated with even greater economic costs and reductions in quality of life. Transcranial magnetic stimulation (TMS) emerges as an effective alternative for treat…